Total: $176.5M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Activiomics Ltd. |
London |
3/16** |
£0.5 ($0.8) |
Activiomics raised $801,000 in a start-up funding round led by IP Group plc |
Aerie Pharmaceuticals Inc. |
Bridgewater, N.J. |
3/8 |
$30 |
Aerie closed a $30M Series B round led by Sofinnova Ventures Partners and Clarus Ventures; other investors were Osage University Partners, Alta Partners and TPG Biotech |
Anergis SA |
Lausanne, Switzerland |
3/29 |
CHF18 ($19.6) |
Anergis raised $19.6M in a Series A round co-led by three European funds |
Arsanis Inc. |
Vienna, Austria |
3/1 |
$10 |
Arsanis closed a $10M Series A round; investors were OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences |
AssureRx Health Inc. |
Cincinnati |
3/28 |
$11 |
AssureRx closed an $11M Series B financing round led by Claremont Creek Venture and Sequoia Capital, with participation by Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech and Allos Ventures |
BerGenBio A/S |
Bergen, Norway |
3/3 |
NOK7 ($1.3) |
BerGenBio secured $1.3M from local Sarsia Seed and Development Funds |
BioNanomatrix Inc. |
Philadelphia |
3/18 |
$23.3 |
BioNanomatrix closed a $23.3M Series B round led by Domain Associates with participation from new investor Gund Investment Corp. and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group |
Euthymics Bioscience Inc. |
Cambridge, Mass. |
3/10 |
$4 |
Euthymics raised $4M to its Series A round led by Novartis Venture Fund and Venture Investors, as well as H&Q Healthcare Investors and H&Q Life Sciences Investors, GGS Venture Partners and Timothy J. Barberich |
Nerium Biotechnology Inc. |
Toronto |
3/11 |
$0.5 |
Nerium completed a nonbrokered private placement of $500,000 to a single U.S. investor for 500,000 Series A convertible preference shares |
NeuroPhage Pharmaceuticals Inc. |
Cambridge, Mass. |
3/2 |
$12.4 |
NeuroPhage raised $12.4M in a Series B round led by Mérieux Développement, with Shire LLC participating |
Nimbus Discovery LLC |
Cambridge, Mass. |
3/11 |
ND |
Nimbus received an extension of its seed round with an investment by Bill Gates and Richard Friesner; Atlas Venture also participated |
Omthera Pharmaceuticals |
Bedminster, N.J. |
3/15 |
$33.9 |
Omthera raised $33.9M in Series B funding led by New Enterprise Associates; they were joined by Sofinnova Partners |
PNP Therapeutics Inc. |
Birmingham, Ala. |
3/11 |
$1.2 |
PNP received a second round of funding worth about $1.2M |
Polyplus-Transfection SA |
Strasbourg, France |
3/17 |
$3.5 |
Polyplus raised about $3.5M in a funding round involving new investors AIRFI and Sudinnoa and existing shareholders CIC Vizille Capital Innovation and CIC Finance |
Synageva BioPharma Corp. |
Lexington, Mass. |
3/22 |
$25 |
Synageva closed a $25M private equity financing |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. | ||||
